Protein ubiquitination is critical for many cellular processes, through its ability to regulate protein degradation and various signaling mechanisms. In the ubiquitin (Ub) system, substrate specificity is achieved through the E3 family of Ub ligases. Because alterations of the ubiquitination machinery have been reported in human cancers, the selective interference with Ub ligases might represent a powerful therapeutic tool. Here, we report the first wide survey of misregulation of Ub ligases in cancer. We analysed 82 Ub ligases in nine types of cancer by in situ hybridization on tissue microarrays. We found 27 instances in which an Ub ligase was altered in a given type of tumor, when compared with normal tissues: 21 cases of overexpression and 6 cases of underexpression. We further analysed selected Ub ligases in large cohorts of breast and non-small-cell lung carcinomas. In five, of six, of these extended analyses (HUWE1, CCNB1IP1, SIAH1 and SIAH2 in breast cancer and CCNB1IP1 in lung cancer), we found that the levels of Ub ligases correlated significantly with relevant prognostic factors, and with clinical outcome. Our findings show that the alteration of Ub ligases is a frequent event in cancer and identify candidate targets for molecular therapies.
Introduction
Protein ubiquitination is a versatile post-translational modification that regulates numerous aspects of cell physiology. The best-characterized function of ubiquitin (Ub) is to mediate the targeting of proteins to proteasomal degradation. This is achieved through the addition of poly-Ub chains (branching from the K48 of Ub) to target proteins (Hershko and Ciechanover, 1998) . In recent years, however, it has become clear that other forms of ubiquitination, mono-ubiquitination or poly-ubiquitination through non-K48 chains, are involved in many signaling processes, thus defining a vast series of non-degradative functions of Ub (Sigismund et al., 2004; Mukhopadhyay and Riezman, 2007) . Not surprisingly, therefore, defects in Ub-dependent proteolysis and Ub-dependent signaling have been implicated in several human diseases, including cancer, neurodegenerative disease and metabolic disorders (Ciechanover and Schwartz, 2002; Ciechanover, 2003) .
In cancer, the subversion of the Ub system might, in principle, cause misregulation of signaling pathways, or altered degradation of critical cell-cycle regulators. For instance, the malfunction of the Ub-proteasome pathway could either enhance the effect of oncoproteins or reduce the amount of tumor suppressor proteins. Indeed, the Ub system targets several positive growth regulators, for example, N-Myc, c-Myc, c-Fos, c-Jun and Src-like proteins, to proteasomal degradation (Kim et al., 2004; Nakayama and Nakayama, 2006; Weiss et al., 2007; Xia et al., 2007; Zhao et al., 2008) . Similarly, enhanced Ub-proteasome-dependent degradation of tumor suppressor proteins, such as TP53, p27 or for mutated NF2, has also been implicated in the pathogenesis of malignancies (Gautreau et al., 2002; Sun, 2006) . Thus, the ubiquitination machinery is considered a promising therapeutic target for cancer, particularly because its components are enzymes that should, in principle, be druggable. A proof of principle for this approach is provided by the efficacy of proteasome inhibitors in some types of cancer. For instance, Velcade (Millennium Pharmaceuticals, Inc., Cambridge, MA, USA) has recently been approved for the treatment of multiple myeloma and mantle cell lymphoma (Orlowski and Kuhn, 2008) . However, proteasome inhibition is limited to targeting only one function of the Ub system, namely protein degradation, thus failing to target the signaling functions of the system, which might be as relevant to tumorigenesis as its degradative functions. Moreover, given the wide homeostatic significance of Ub-based degradation, its global inhibition is bound to be plagued with undesired toxicity. Thus, strategies to identify specific targets within the Ub system are critical.
The complex molecular nature of the process of ubiquitination might offer keys to enter into the issue of specificity. The ubiquitination machinery is structured in a hierarchical cascade, in which three types of enzymes (E1, E2 and E3) act sequentially to promote the transfer of Ub onto substrates (Hershko and Ciechanover, 1998) . In some cases, a multi-Ub chain assembly factor (E4) is also involved (Hoppe, 2005) . Substrate specificity is achieved through the E3 Ub ligase family of proteins. Two major types of molecules execute this function: HECT-type E3 ligase possesses intrinsic Ub ligase activity and directly catalyses the transfer of Ub onto substrates. RING-type E3 ligase functions as specific adaptors, bridging together E2 (Ub-conjugating) enzymes and their substrates, thereby allowing E2 to catalyse the Ub transfer. There are more than 100 known E3s. On the one hand, this projects the possibility of specific therapeutic intervention, through inhibition of individual E3s. On the other, with reference to cancer, it poses the problem of compiling a precise atlas describing which E3 is altered in which cancer, an issue that has been probed so far by one-molecule-at-atime approaches, that is by analysing individual E3 ligases in single types of cancer (see detailed reference list in Supplementary information). In this study, we describe the first wide survey of misregulation of Ub ligases in cancer.
Results

Study design
A schematic of the study design is depicted in Figure 1a . We analysed a total of 82 Ub ligases (28 HECTs and 48 RINGs, and 6 E4 enzymes, selected as described in Materials and methods, listed and referenced in Supplementary Table 1) . Since the beginning of our screening, other RING-E3s have been identified (Kallijarvi et al., 2005; Meroni and Diez-Roux, 2005; Buchwald et al., 2006; Schauvliege et al., 2006) . Thus, our collection of Ub ligases is not exhaustive, although it contains the majority of enzymes known so far. We used in situ hybridization (ISH) on tissue microarray (TMA) as the screening platform. This choice was based on a number of reasons. First, a large-scale expression study must necessarily be based on RNA detection, because the availability of suitable antibodies (especially for in situ detection) constitutes a major limiting factor for protein detection-based approaches. Second, among RNA-based technologies, ISH/TMA couples the advantages of a medium/high-throughput methodology (hundreds of genes can be screened on hundreds of tumors) with those of a high-resolution technology (each core can be analysed by visual inspection, thereby allowing the identification of the cellular origin of the signal in a heterogeneous tissue). Third, ISH/TMA can be carried out on archival paraffin-embedded samples, which is extremely advantageous for validation studies on large case collections for which patient follow-up is available. Fourth, we have already used ISH/TMA for large screening projects and showed that its results correlate well with those obtainable with more quantitative methods, such as quantitative PCR (Nicassio et al., 2005; Capra et al., 2006; Vecchi et al., 2008) .
The initial ISH/TMA screening led to the identification of 13 ligases that were misregulated in human cancers, for a total of 27 misregulation occurrences ( Figure 1a ). Selected ligases from this group were subjected to further validation by analysing their ability to predict disease outcome in two cohorts of breast cancer patients and in one cohort of non-small-cell lung carcinomas (NSCLCs) (Figure 1a) .
Alterations in the expression of Ub ligases in human cancers Our TMAs contained samples from nine types of cancer, including breast, colon-rectum, lung, prostate, larynx, stomach, uterus, kidney carcinomas and non-Hodgkin lymphomas. Together, these types of cancer account for 65-70% of all cancer incidence, and for 60-65% of all cancer deaths in the United States (source National Cancer Institute, http://seer.cancer.gov/statfacts/). We screened, on average, B200 tumors per gene, and a roughly equal number of normal tissues (frequently, and whenever possible, from the same patient; details are given in Supplementary Table 2) .
Of 82 analysed ligases, 13 (B16%) could be detected (ISH score X1, see Materials and methods) in at least one of the analysed tissue types (Figure 1b and  Supplementary Table 3 ; high-power views of representative ISH are shown in Supplementary Figures 1-3) . The remaining 69 (B84%) genes showed completely negative or barely detectable signals in all the analysed tissues, likely due to low mRNA abundance. These results are in accordance with previous reports showing low mRNA expression of HECT-type E3s in human cells lines (Scarafia et al., 2000) . It can be noted that in all cases in which antisense probes yielded positive signals (13 genes), the corresponding sense probe, used as a negative control, did not yield any appreciable signal (data not show). In addition, we selected three representative ligases (HUWE1, SIAH2 and CCNB1IP1, for which we also carried out an extended analysis in breast and lung cancer, see below) and performed RNA interference in cell lines. The interfered cells were then included in paraffin and subjected to ISH, as described for the normal and tumor tissues. In Figure 4) . Alterations in the levels of expression of the 13 detectable Ub ligases in human cancers were evaluated through comparison of the average expression levels between tumor cells and cells of putative origin of a given tumor, when known, in the normal tissue counterpart (see Supplementary Methods, Figure 1b and Supplementary Table 4 for detailed information). All 13 ligases were found to be significantly misregulated in at least one type of tumor. We detected 27 instances in which one of the Ub ligases was misregulated in a given type of tumor. Of these events, 21 represented overexpression and 6 represented underexpression (Figure 1b, Supplementary Table 4 and Supplementary  Figures 1-3 ).
In conclusion, our expression survey showed misregulation of Ub ligases at a relatively high frequency in human cancers. In all cases (13) in which Ub ligases could reliably be detected, they showed alterations in at least one type of cancer. It can be noted that in all cases, the ISH signals of the overexpressed or underexpressed genes were associated with the tumor cell component and not with the adjacent or infiltrating stroma (see Figure 1c for representative examples and Supplementary Table 4 for details).
Misregulation of HUWE1, CCNB1IP1, SIAH2 and SIAH1 predicts clinical outcome in breast cancer
If alterations in the expression of E3s have a role in the development or in the natural history of certain cancers, significant correlations with clinically relevant parameters should be expected. As a proof-of-principle validation of this concept, we carried out an in-depth characterization of selected E3s in breast and lung carcinomas, which together accounts for more than one-third of all cancer deaths in the United States (source National Cancer Institute, http://seer.cancer. gov/statfacts/).
For breast studies, we initially selected three ligases: HUWE1 (overexpressed in breast cancer), and SIAH2 and CCNB1IP1 (both underexpressed in breast cancer). Their expression was determined in a 'case-control' cohort composed of 444 breast tumor samples (clinical and pathological information is given in Supplementary  Table 5 ). In univariate analysis, low levels of expression of each of the three ligases significantly correlated with higher risks of disease recurrence (Table 1, see also  Supplementary Table 6 for correlations between the levels of expression of the three ligases and clinical and pathological parameters in the case-control cohort). In a multivariate analysis, in which all events were evaluated in relation to relevant prognostic factors (age, pathological stage, tumor grade, hormone-receptor status, nodal status, Ki-67 and ErbB2 expression), SIAH2, HUWEI and CCNB1IP1 provided a significant independent predictive power of a reduced disease recurrence (Table 1) . Because SIAH2 and CCNB1IP1 were the most predictive genes, we investigated the effect of their coincident misregulation in the natural history of breast cancer. As shown in Table 1 , patients whose tumors displayed low expression of both genes had a much higher risk of disease recurrence.
To further refine our analysis, and in order to have a precise assessment of the probability of disease-free survival in time as a function of Ub ligase expression (something that cannot be assessed in a case-control study), we tested the expression of SIAH2 on a second cohort of patients ('consecutive' cohort), comprising 477 consecutive pT1-2 patients (clinical and pathological information is given in Supplementary Table 5 ). We also screened SIAH1 on this cohort of patients, because this Ub ligase-which belongs to the same family of SIAH2-was underexpressed in breast cancer (Figure 1b ). Low levels of expression of both SIAH1 and SIAH2 correlated significantly with decreased probability of disease-free survival, both by the KaplanMeyer analysis (Figures 2a and b) and by univariate and multivariate analysis (Table 1, see also Supplementary  Table 6 for correlations between the levels of expression of the two ligases and clinical and pathological parameters in the consecutive cohort).
E3 ligases in lung cancer
In our initial screening, two E3s were found misregulated in lung cancers, HERC1 and HUWE1 (both overexpressed). The levels of expression of HERC1 were, however, rather low, and thus this E3 was excluded from further analysis. In addition to HUWE1, we added CCNB1IP1 to our extended analysis, despite the fact that this ligase was not apparently misregulated in lung cancers in our initial survey (Figure 1b) . We did so because, by closely inspecting the results of the initial screening, we noticed that, in the normal lung, CCNB1IP1 was expressed in bronchial cells (mainly in the basal layer) but not in alveolar cells. Conversely, in lung tumors, many tumors displayed no signal at all in any cytotype (data not shown). This finding, although highlighting one of the advantages of using an in situ technique for this kind of studies, prompted us to hypothesize that perhaps CCNB1IP1, similarly to what happens in breast cancer, is underexpressed even in lung tumors and that tissue heterogeneity biased our initial assessment. Thus, we decided to further characterize this ligase.
A large cohort of consecutive NSCLCs (clinical and pathological features are given in Supplementary  Table 7) arrayed on TMAs was therefore characterized for the expression of HUWE1 and CCNB1IP1 (see also Supplementary Table 8 for correlations between the levels of expression of the two ligases and clinical and pathological parameters in the NCSLC cohort). Fiveyear survival analysis was conducted on 357 patients for whom follow-up was available (see Supplementary  Methods and Supplementary Table 7) . We carried out Kaplan-Meier estimates of overall survival as a function of the levels of expression of CCNB1IP1 and HUWE1 (Figure 3 ). Low CCNB1IP1 expression was significantly associated with shorter overall survival (log rank P ¼ 0.04). When NSCLC patients were stratified by tumor histotype, a significant correlation was maintained for squamous cell carcinomas (P ¼ 0.03) but not for adenocarcinomas (P ¼ 0.35). In a multivariate proportional-hazard modeling of overall survival including tumor grade age, ki67 level, p53 status, tumor size and stage, CCNB1IP1 was found to be independently associated with overall survival in NSCLC (hazard ratio (HR) ¼ 1.658, 95% CI ¼ 1.04-2.65, P ¼ 0.03). No significant association between HUWE1 and overall survival was found (data not shown).
Discussion
We report here the first wide survey of misregulation of Ub ligases in human cancer. We identified 13 ligases whose levels of expression were altered in at least one type of cancer. The predominant alteration was overexpression, in line with the known or suspected function of many E3s of targeting degradation of negative regulators of the cell-cycle or positive regulators of apoptosis (Nakayama and Nakayama, 2006) . However, we also detected a significant number of underexpressions, compatible with a possible tumor suppressor role of some of these enzymes, as previously hypothesized (Nakayama and Nakayama, 2006) . In our extended analyses with selected Ub ligases, we found that the levels of expression of these enzymes identified subclasses of breast and lung carcinomas with different clinical outcomes, arguing that misregulation of these Ub ligases has clinical implications. Finally, at least in the case of SIAH2 and CCNB1IP1 in breast cancer, tumors harboring dual misregulation displayed more aggressive behavior, when compared with those characterized by single alterations of the two ligases, suggesting a biological interplay whose nature remains to be established.
Some of the Ub ligases analysed in this study were already known to be altered in individual types of tumors or in cancer cell lines (a comprehensive Tables 1 and 3 for relevant references). However, our analysis, when viewed as a whole, showed an unsuspected extent of involvement of these enzymes in human cancers. Strikingly, in all cases in which Ub ligases were reliably detectable by ISH/TMA, they displayed misregulation in at least one type of tumor, and frequently in more than one type. These results predict that technologies capable of exploring mRNA levels with a wider dynamic range than ISH/TMA might unveil additional misregulations (possibly at similarly high frequency as those reported here) even in the subgroup of Ub ligases that were under the detection level by our ISH/TMA methodology. From our extended analysis of breast and lung cancer, CCNB1IP1 emerges as a very interesting candidate for a tumor suppressor role in these neoplasias. CCNB1IP1 was underexpressed in breast cancer and most likely also in NSCLC. In both type of tumors, the downregulation of CCNB1IP1 was associated with aggressive disease, and predicted poor prognosis. Some of the known molecular functions of CCNB1IP1 would support a tumor suppressor role. This ligase controls the degradation of Cyclin B1 (Toby et al., 2003) , projecting elevated levels of this cyclin in CCNB1IP1-deficient cells. Overexpression of Cyclin B1, in turn, has been reported in various human tumors, and it is a predictor of poor prognosis (Wang et al., 1997; Soria et al., 2000; Dong et al., 2002; Hassan et al., 2002; Yasuda et al., 2002) . High levels of Cyclin B1 might cause misregulation of the Cyclin B1/Cdk1 complex, allowing escape from the G2-M checkpoint induced by DNA damage (Lobrich and Jeggo, 2007) . Interestingly, and compatible with this possibility, CCNB1IP1 is needed to maintain the accurate euploid segregation at the meiotic prophase I-metaphase I boundary (Ward et al., 2007) and the mitotic G2-metaphase boundary (Toby et al., 2003) .
Our studies also indicated the misregulation of both SIAH2 and SIAH1 in breast tumors. Both these ligases were underexpressed, suggesting a putative tumor suppressor role. Although the biological functions of SIAH2 are poorly characterized, available molecular knowledge for SIAH1 supports such a role. SIAH1 is a p53 target gene (Fiucci et al., 2004) , and it is involved in at least one p53-mediated cellular response, that is, the degradation of b-catenin. Through this pathway, which relies on an APC/Skip1/Ebi/SIP/SIAH1 circuitry and is alternative to the canonical Axin/GSK3b-based mechanism (Liu et al., 2001; Matsuzawa and Reed, 2001) , SIAH1 contributes to p53-mediated cell-cycle arrest (Matsuzawa and Reed, 2001) . Thus, the downregulation of SIAH1 might contribute to breast cancer by attenuating a p53-dependent tumor suppressor pathway.
The most frequently misregulated ligase in our screening was HUWE1, which was overexpressed in seven of nine types of tumors, in line with its reported overexpression in several types of cancers and cancer cell lines (Adhikary et al., 2005; Yoon et al., 2005) . The analysis of large case collections of breast and lung cancer allowed establishing that high levels of HUWE1 are present in B10% of these tumors (Supplementary  Tables 6 and 8 Table 1 . Analyses were carried out on the consecutive cohort of samples.
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S Confalonieri et al circuitries that regulate: (i) p53 activity (Chen et al., 2005) , (ii) p53-independent anti-proliferative pathways (Chen et al., 2005) and (iii) myc transcriptional activity (Adhikary et al., 2005) . In principle, several of the putative functions of HUWE1 would be compatible with an oncogenic role and with its actual overexpression in tumors (Adhikary et al., 2005; Yoon et al., 2005;  and this paper). It must be noted, however, that the precise molecular functions of HUWE1 and their biological consequences are presently the matter of debate (Bernassola et al., 2008) . For instance, both antiapoptotic and pro-apoptotic effects of the functional ablation of HUWE1 have been reported (Chen et al., 2005; Zhong et al., 2005; reviewed in Bernassola et al., 2008) . Thus, alternative scenarios are also worth considering. One possibility, which would also be compatible with the fact that HUWE1 is overexpressed in the greatest majority of types of tumors, is that the misregulation of HUWE1 is a consequence of transformation. HUWE1 is involved in the degradation of CDC6 after DNA damage, and it has been proposed to represent the primary effector of CDC6 degradation in p53-null cells, where the canonical p53-mediated/APC-dependent mechanism of CDC6 degradation is attenuated (Hall et al., 2007) . CDC6 is required for licensing of replication origins before the onset of DNA replication in eukaryotic cells (Pelizon, 2003) , and overexpression of CDC6 has been observed in several tumor types (Borlado and Mendez, 2008 ; and reference therein), possibly contributing to genomic instability (Oehlmann et al., 2004; Lau et al., 2006) . Thus, rather than being a tumor-inducing event, HUWE1 overexpression might be a marker of p53 inactivation and CDC6 overproduction in cancer cell, and its protective function would be to target the degradation of excess CDC6 in the absence of a functional APC. Compatibly with this possibility, in breast cancers, low levels of HUWE1 correlate with a higher risk of recurrence and that there is significant correlation between high levels of HUWE1 and detectable p53 (a sign of mutated p53) (see Supplementary Table 9) .
Although the molecular scenarios depicted above will need further experimental corroboration, our findings provide a broad atlas of the alteration of Ub ligases in human cancers, and point to several possible druggable targets, thereby supporting the idea that specific inhibition of Ub ligases might prove effective in a sizable fraction of human cancers. Moreover, we bring to light the prognostic value of some of these genes, thus opening the way for further studies focused on their validation as cancer biomarkers.
Materials and methods
Identification and selection of Ub ligases
HECT-type E3 ligases were identified by profile-based searches of protein databases and from literature. Initial domain information was collected from the SMART (http://smart. embl-heidelberg.de/) and the Pfam (http://pfam.janelia.org/) databases. The profile for the HECT domain was built using the HMM software starting from multiple alignment of protein sequences. This profile was used to search all the public protein databases using the HMMER software (http:// hmmer.janelia.org/). After elimination of redundancies, we identified 28 unique human proteins bearing an HECT domain (Supplementary Table 1 For RING-type E3s, several searches were carried out with domain profile obtained by the SMART database. This, however, led to the identification of many 'dubious positives': essentially known transcription factors, displaying a RINGfinger domain, for which no immediate Ub ligase function could be evinced from the literature. We also used several pattern searches, using the Prosite database (http://www. expasy.ch/prosite/); in this case, patterns were derived from literature or directly from the Prosite database. Again, no single pattern could collect all known RING-type E3 ligase, and still several 'dubious positive' hits were selected. Thus, we turned to the literature and built a list of bona fide RING-type ligases, for which Ub ligase activity was experimentally proved. The same procedure was used to select E4 enzymes. The complete list of selected proteins (and the relevant references) is reported in Supplementary Table 1 .
In total, we selected 82 Ub ligases (28 HECTs, 48 RINGs and 6 E4s). We excluded some well-characterized E3s, such as the multi-subunit SCF (Skip1/Cull/F-BOX protein) and APC/ C (anaphase-promoting complex/cyclosome) E3s, because their roles in cell-cycle control and human cancers have been already extensively characterized (Nakayama and Nakayama, 2006) .
Representative cDNAs for each gene were retrieved from our in-house Unigene EST clone collection (Unigene build no. 106), or obtained from Invitrogen (http://clones.invitrogen. com/) or RZPD (http://www.rzpd.de/ now imaGenes http:// www.imagenes-bio.de/). Multiple clones for each Ub ligase were selected, sequence verified and used as templates to design hybridization probes for the ISH/TMA analysis. BLAST searches were performed to identify the most specific 300 bp region of each clone, and riboprobes were synthesized as described previously (Capra et al., 2006) .
Tissue samples and TMA design for the initial large-scale screening For the large-scale ISH/TMA study, formalin-fixed and paraffin-embedded tumor and normal samples were provided by the Pathology Departments of Ospedale Maggiore (Novara), Presidio Ospedaliero (Vimercate), Ospedale San Paolo (Milano) and Ospedale Sacco (Milano). Samples were arrayed in different TMAs (Supplementary Table 2) , prepared essentially as previously described (Kononen et al., 1998) . Briefly, two representative normal (when available) and tumor areas (diameter 0.6 mm) from each sample, previously identified on hematoxylin-eosin-stained sections, were removed from the donor blocks and deposited on the recipient block using a custom-built precision instrument (Tissue Arrayer-Beecher Instruments, Sun Prairie, WI, USA). Sections of 2 mm thickness of the resulting recipient block were cut, mounted on glass slides and processed for ISH.
ISH/TMA analysis on large cohorts of breast and lung cancer patients For the in-depth analyses of representative E3 ligases, we used breast and lung cancer samples from non-treated patients. Validation studies were performed on three different cohorts of samples.
Breast cancer case-control cohort. This cohort consisted of patients (median age 51, range 24-84 years) operated at the European Institute of Oncology (Milan, Italy) for primary breast cancer (enrollment period, 1994-1997) . A total of 444 women with breast cancer were selected according to the pathological characteristics of the primary tumor (nodal status) and upon follow-up information, in order to have a representative number of event and event-free cases. Of these, 211 women who developed an event (loco-regional relapse, distant metastasis or contralateral breast cancer) within 7 years from the first breast cancer surgery constituted the cases, whereas 233 women who were alive and free of any event after 7 years of follow-up constituted the controls. Clinical and pathological characteristics are given in Supplementary Table 5 .
Breast cancer consecutive cohort. This cohort was from a surgical trial conducted at the European Institute of Oncology (Milan, Italy) between March 1998 and December 1999 (Veronesi et al., 2003) involving 447 consecutive patients (median age 55.8, range 37-75 years) with small-size primary breast cancers (pT1 and pT2o3.0 cm in diameter) and a mean follow-up period of 65 months. Clinical and pathological characteristics are given in Supplementary 
ISH
In situ hybridization was carried out as previously described (Capra et al., 2006) . All TMAs were first analysed for the expression of the housekeeping gene b-actin to check for the mRNA quality of the samples. Cases showing absent or low b-actin signal were excluded from the analysis (data not shown). Gene expression levels were evaluated by counting the number of grains per cell and were expressed in a semiquantitative scale (ISH score) as follows: 0 (no staining), 1 (1-25 grains; weak staining), 2 (26-50 grains, moderate staining) and 3 (>50 grains, strong staining) (Capra et al., 2006) . Misregulation (upregulation or downregulation) was attributed when differences in mean expression levels between the tumor and the normal groups were statistically significant. To determine the clinico-pathological and survival correlations, samples were grouped into low-expressing (TMA score p1) or high-expressing (TMA score >1) tumors, based on the mean of the expression levels of each gene between the two representative cores of the same sample.
It should be noted that the number of scored cases, in some experiments, is lower than the total number of arrayed cases. This is due to a number of reasons: (i) all cores that showed low b-actin signal in the control hybridization were excluded from further consideration; (ii) in some cases, individual cores detached from the slide during the manipulations. For instance, in Figure 2 , SIAH1 and SIAH2 expression was scored in 431 and 455 out of 477 samples, respectively; in Figure 3 , CCNB1IP1 expression was scored in 307 out of 357 samples.
Statistical analysis
Overexpression or underexpression (Figure 1b and Supplementary Table 4 ) was determined using Student's t-test. The association between the clinico-pathological features of the tumors and gene expression was evaluated by Fisher's exact test. In the breast cancer case-control cohort, logistic regression was used to assess the association between gene expression and the presence or absence of events after 7 years of follow-up. Multivariate analysis was used to assess the independent prognostic value of gene expressions after adjustment for recognized prognostic factors, as indicated. In the breast cancer consecutive cohort, disease-free interval was calculated from the date of surgery to the date of the first recurrence or the date of last follow-up. Follow-up was censored at 5 years. In the lung cancer cohort, overall survival analysis was carried out using 5 years censored follow-up. From the original cohort composed of 420 samples, patients who died after surgery within 5 months and without or with follow-up o5 months were excluded from the survival analysis (N ¼ 63). The association between the clinico-pathological features of the tumors and gene expression was evaluated by Fisher's exact test (Supplementary Table 8) , considering the entire cohort of patients (N ¼ 420). Survival curves according to gene expression were drawn using the Kaplan-Meier method and compared by the log-rank test. Multivariate analysis was carried out by means of Cox's proportional hazards model. Analyses were carried out using SAS statistical software (SAS Institute Inc., Cary, NC, USA). All P-values were two-sided. A P-value p0.05 was considered significant.
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